Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
22.25 SEK | -1.98% | +14.10% | +43.92% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.92% | 73.13M | |
+15.54% | 78.65B | |
+9.32% | 8.94B | |
-10.76% | 5.16B | |
+54.31% | 4.85B | |
+11.19% | 4.19B | |
-22.37% | 2.32B | |
+12.41% | 2.29B | |
-30.09% | 2.19B | |
+20.63% | 2.19B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo Obtains First US Patent for Nasal Epinephrine Product